Resource Center

More to Explore - Information About Blood Cancers for Patients, Families and Healthcare Professionals

The Word:


May 21, 2013 - Living with Slow-Growing Lymphoma

Your order contains  item(s)  View Order

Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.

Date: Tuesday May 21, 2013
Time: 1:00 p.m. - 2:30 p.m. ET
Location: Telephone/Web
Read: Program Slides | Transcript
Listen: Presentation | Q&A Session | Extended Q&A
Access: Virtual Lecture

Topics Covered

  • Follicular and other slow-growing lymphomas
  • Current and emerging treatments, including stem cell transplant, for follicular and other slow-growing lymphomas
  • The role of clinical trials in the advancement of treatment
  • Patient-provider communications about treatment options, including clinical trials
  • Patient-provider communications about side effects management


Stephen M. Ansell, MD, PhD
Professor of Medicine
Division of Hematology
Department of Internal Medicine
Mayo Clinic
Rochester, MN

Questions Asked by the Slow-Growing Lymphoma Community

  • What does grade 3 follicular lymphoma mean and how are follicular lymphomas graded?
  • Could you speak a little bit more about maintenance rituximab (Rituxan®) therapy?
  • Are six rounds of Ritxuan and bendamustine (Treanda®) necessary or can one get by on fewer rounds if the therapy is working?
  • Would Rituxan maintenance be a good idea or would watch and wait be a better treatment option after a second relapse with follicular lymphoma?
  • Please talk about the role and outcomes of radioimmunotherapy as a treatment option for slow-growing lymphomas.
  • What would be the best sort of chemical combination to use after relapsing with small B-cell lymphocytic lymphoma? 
  • Does age at diagnosis change the prognosis or the course of the disease?
  • Is it possible to become resistant to Rituxan if a patient hasn't been treated with it for a while?
  • If a patient is resistant to Rituxan, is the patient likely to be refractory to ofatumumab (Arzerra®) as well as the other CD20 antibodies?
  • Is follicular non-Hodgkin lymphoma inherited?
  • Can Rituxan increase LDH levels months after chemo treatment? 
  • What is considered a relapse after Rituxan maintenance for two years?
  • Can one have an allogeneic transplant if their bone marrow is involved with the lymphoma?
  • If a patient has a diagnosis of subcutaneous panniculitis-like T-cell lymphoma and is treated with cyclosporine with a combination of prednisone, was weaned off the cyclosporine but still on maintenance prednisone, would the patient be able to go back on the cyclosporine if it worked before?
  • Besides the BTK inhibitor, are there any other new tyrosine kinase inhibitors that show promise?
  • How do treatments affect the bone marrow? 
  • When will some of these novel treatments and drugs in clinical trials be available more widely?
  • Do you have to be near a clinical trial site to participate?
  • What are CDK inhibitors?
  • Should I be concerned about radiation from the monitoring scans?
  • Are severe leg cramps a side effect of cancer treatment?
  • Can you go back a stage? For instance, if you're in stage III, can you go back to stage II if you have a lymph node removed?
  • Can you talk about ibrutinib and what would it mean for Waldenstrom's macroglobulinemia?
  • Would Medicare pay for ibrutinib if it is approved or only for the specific lymphomas it's been approved for?
  • Is it possible to be over-treated?
  • What percentages of people are in remission from follicular lymphoma?
  • If lymphoma is in the bone marrow, will it ever spread to other areas in the body?
  • Is Idiopathic thrombocytopenic purpura (ITP) related to low grade lymphoma or is it something totally different?

Sponsors and Supporters

This program is sponsored by The Leukemia & Lymphoma Society and supported by grants from Genentech and Biogen Idec and Spectrum Pharmaceuticals.

last updated on Friday, April 17, 2015